Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection

Journal of Infectious Diseases

Volumn 217, Issue 2, 2018, Pages 223-231

  Rimoin, Anne W ^a   Lu, Kai ^b   Bramble, Matthew S ^a,c   Steffen, Imke ^b   Doshi, Reena H ^a   Hoff, Nicole A ^a   Mukadi, Patrick ^d   Nicholson, Bradly P ^e   Alfonso, Vivian H ^a   Olinger, Gerrard ^f,g   Sinai, Cyrus ^a   Yamamoto, Lauren K ^b   Ramirez, Christina M ^a   Okitolonda Wemakoy, Emile ^h   Kebela Illunga, Benoit ⁱ   Pettitt, James ^f   Logue, James ^f   Bennett, Richard S ^f   Jahrling, Peter ^f   Heymann, David L ^j,k   Piot, Peter ^k   Muyembe Tamfum, Jean Jacques ^d   Hensley, Lisa E ^f,g   Simmons, Graham ^b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d Institut National de Recherche Biomedicale   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

^f Integrated Research Facility   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h Kinshasa School of Public Health   (United States)

ⁱ Kinshasa Gombe and Goma   (France)

^j ROYAL INSTITUTE OF INTERNATIONAL AFFAIRS   (United Kingdom)

^k LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

Democratic Republic of the Congo; Ebola virus; filovirus; serological response; virus neutralization

Indexed keywords

NEUTRALIZING ANTIBODY; PROTEIN VP40; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; EBOLA HEMORRHAGIC FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; MIDDLE AGED; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; SEROLOGY; SURVIVOR; VERY ELDERLY; VIRUS NEUTRALIZATION; ZAIRE EBOLAVIRUS; ADOLESCENT; BLOOD; DEMOCRATIC REPUBLIC CONGO; EBOLAVIRUS; EPIDEMIOLOGY; IMMUNOLOGY; QUESTIONNAIRE; SERODIAGNOSIS; TIME FACTOR; VIRAL PLAQUE ASSAY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DEMOCRATIC REPUBLIC OF THE CONGO; DISEASE OUTBREAKS; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; SURVEYS AND QUESTIONNAIRES; SURVIVORS; TIME FACTORS; VIRAL PLAQUE ASSAY; YOUNG ADULT;

EID: 85040548624     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix584     Document Type: Article

References (32)

1. Beeching NJ, Fenech M, Houlihan CF. Ebola virus disease. BMJ 2014; 349:g7348.
2. Anon. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56:271-93.
3. Centers for Disease Control and Prevention. Cases of Ebola virus disease in Africa, 1976-2015. https://www. cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html. Accessed 14 March 2016.
4. Maganga GD, Kapetshi J, Berthet N, et al. Ebola virus disease in the Democratic Republic of Congo. N Engl J Med 2014; 371:2083-91.
5. WHO Ebola Response Team, Aylward B, Barboza P. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371:1481-95.
6. Muyembe-Tamfum JJ, Mulangu S, Masumu J, Kayembe JM, Kemp A, Paweska JT. Ebola virus outbreaks in Africa: Past and present. Onderstepoort J Vet Res 2012; 79:451.
7. Breman JG, Heymann DL, Lloyd G, et al. Discovery and description of Ebola Zaire virus in 1976 and relevance to the West African epidemic during 2013-2016. J Infect Dis 2016; 214(Suppl 3):S93-101.
8. Rosello A, Mossoko M, Flasche S, et al. Ebola virus disease in the Democratic Republic of the Congo, 1976-2014. Elife 2015; 4.
9. Natesan M, Jensen SM, Keasey SL, et al. Human survivors of disease outbreaks caused by Ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses. Clin Vaccine Immunol 2016; 23:717-24.
10. Corti D, Misasi J, Mulangu S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 2016; 351:1339-42.
11. Bond N, Schieffelin JS, Moses LM, Bennett AJ, Bausch DG. A historical look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute infection. Am J Trop Med Hyg 2013; 88:241-4.
12. Johnson KM, Webb PA, Heymann DL. Evaluation of the plasmapheresis program in Zaire. Ebola virus hemorrhagic fever. In: Pattyn SR (ed). Ebola virus hemorrhagic fever. Amsterdam: Elsevier, 1978.
13. World Health Organization. Case definition recommendations for Ebola or Marburg Virus Diseases. Technical Guidelines for Integrated Disease Surveillance and Response (IDS) in the Africa Region. Geneva: World Health Organization, 2014.
14. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000; 6:886-9.
15. Burbelo PD, Goldman R, Mattson TL. A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol 2005; 5:22.
16. Wilkinson DE, Page M, Mattiuzzo G, et al. Comparison of platform technologies for assaying antibody to Ebola virus. Vaccine 2017; 35:1347-52.
17. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci USA 2004; 101:4240-5.
18. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 2002; 76:2518-28.
19. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 2005; 102:11876-81.
20. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995; 206:935-44.
21. Zhou Y, Steffen I, Montalvo L, et al. Development and application of a high-throughput microneutralization assay: Lack of xenotropic murine leukemia virus-related virus and/or murine leukemia virus detection in blood donors. Transfusion 2012; 52:332-42.
22. Wrensch F, Karsten CB, Gnirß K, et al. Interferon-induced transmembrane protein-mediated inhibition of host cell entry of Ebolaviruses. J Infect Dis 2015; 212(Suppl 2):S210-8.
23. Warfield KL, Aman MJ. Advances in virus-like particle vaccines for filoviruses. J Infect Dis 2011; 204(Suppl 3):S1053-9.
24. Aleksandrowicz P, Marzi A, Biedenkopf N, et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J Infect Dis 2011; 204(Suppl 3):S957-67.
25. Leroy EM, Baize S, Mavoungou E, Apetrei C. Sequence analysis of the GP, NP, VP40 and VP24 genes of Ebola virus isolated from deceased, surviving and asymptomatically infected individuals during the 1996 outbreak in Gabon: Comparative studies and phylogenetic characterization. J Gen Virol 2002; 83:67-73.
26. Qiu X, Alimonti JB, Melito PL, Fernando L, Ströher U, Jones SM. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 2011; 141:218-27.
27. Sobarzo A, Groseth A, Dolnik O, et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis 2013; 208:299-309.
28. Ji X, Olinger GG, Aris S, Chen Y, Gewurz H, Spear GT. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 2005; 86:2535-42.
29. Kajihara M, Marzi A, Nakayama E, et al. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J Virol 2012; 86:13467-74.
30. Becquart P, Wauquier N, Mahlakõiv T, et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One 2010; 5:e9126.
31. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 2001; 124:453-60.
32. Global Health Observatory World Health Organization. Democratic Republic of the Congo: Country Profiles. http://www.who.int/gho/countries/cod/country-profiles/en/. Accessed 18 November 2017.